Zulu
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Imikhiqizo Izigaba
Imikhiqizo efakiwe
Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo

Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo
I-Telmisartan I-antihypertensive Protecting renal engcono

I-Telmisartan I-antihypertensive Protecting renal engcono
I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha

I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha
I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers

I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers
I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control

I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control
I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders
I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition

I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition
I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba

I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba
I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa

I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa
0102030405
I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Intengo yesithenjwa: USD 8-15/g

  • Igama Lomkhiqizo I-Trametinib
  • Inombolo ye-CAS. 871700-17-3
  • MF I-C26H23FIN5O4
  • MW 615.402623
  • Ukuminyana 1.743
  • Iphoyinti lokuncibilika 293-303°C
Xhumana nathi
imininingwane yomkhiqizo

Incazelo Eningiliziwe

I-Trametinib iyi-kinase inhibitor enamandla futhi ekhethayo esetshenziswa ngokuyinhloko ekwelapheni i-melanoma engabukeki noma ye-metastatic ngokuguqulwa kwe-BRAF V600, kanye nezinhlobo ezithile zomdlavuza wamaphaphu osezingeni eliphezulu noma we-metastatic ongewona omncane. Lesi sihloko sihlola indlela yokusebenza, izinkomba zomtholampilo, kanye nezinzuzo ze-trametinib ekwelapheni umdlavuza we-BRAF V600 oguquguqukayo.

I. Ukuqonda i-Trametinib:
A. I-Oral, enamandla, futhi i-kinase inhibitor ekhethiwe
B. Owesigaba se-MEK inhibitors
C. Ivimba umsebenzi we-kinase we-MEK1 kanye ne-MEK2
D. Ivimbela umfula i-ERK1 kanye nokusayina kwe-ERK2

II. Izinkomba Zomtholampilo:
A. Imelanoma engabukeki noma ye-metastatic ephethe ukuguqulwa kwe-BRAF V600:
Ukwelashwa okuhlangene ne-dabrafenib mesylate
B. Ukwelashwa kwe-adjuvant kwangemva kokuhlinzwa kwe-BRAF V600 mutation-positive melanoma:
Ukwelashwa kwe-Adjuvant nge-dabrafenib mesylate ngemva kokukhishwa okuphelele

17161152266097be

III. Iqhaza Kumdlavuza wamaphaphu Ongewona Amancane:

A. Umdlavuza wamaphaphu weseli ongewona omncane njengembangela ehamba phambili yokugula nokufa

B. Izinga lokuguqulwa kofuzo lwe-BRAF kanye nokusabalala kokuguqulwa kwe-BRAF V600E

Umphumela wokuvimbela we-C. Trametinib kumaseli e-BRAF V600 mutation-positive melanoma


IV. Indlela Yesenzo:

A. Ukuvinjelwa okubuyiselekayo kwe-mitogen-activated extracellular signal-regulated kinase (MEK) 1 kanye ne-MEK2

B. Umthelela kumzila we-MAPK kanye nephrotheni ye-MEK

C. Ukuvinjelwa kokwanda kwamaseli kanye nendlela ye-ERK engezansi


V. I-Postoperative Adjuvant Therapy:

A. Izinzuzo zokwelashwa okuhlanganisiwe okuhlosiwe ne-Dabrafenib ne-Trametinib

B. Izinzuzo zesikhathi eside, eziqinile ze-recurrence-free survival (RFS) ezisesigabeni se-III sengozi ephezulu ye-BRAF yeziguli ze-melanoma eziguqukayo.



I-Trametinib, i-kinase inhibitor eqondisiwe, ikhombisa ukusebenza ngempumelelo okubalulekile ekwelapheni umdlavuza we-BRAF V600 oguquguqukayo, ikakhulukazi i-melanoma engabukeki noma ye-metastatic kanye nezinhlobo ezithile zomdlavuza wamaphaphu ongewona omncane. Indlela yayo yokusebenza, evimbela umsebenzi we-MEK1 kanye ne-MEK2 kinase, iholela ekuvinjweni kwendlela ye-ERK engezansi kanye nokucindezelwa kokwanda kwamaseli. I-Trametinib, ihlanganiswe ne-dabrafenib mesylate, inikeza izinzuzo zokwelashwa kuzo zombili izilungiselelo ezithuthukile ne-adjuvant ezigulini ze-BRAF V600 mutation-positive melanoma.
Xhumana nathi ukuze uthole iseluleko semithi nolwazi lwamanani entengo ukuze uthuthukise ukunakekelwa kwesiguli.

Ukucaciswa

171611254334271z